Drugmaker Sanofi-Aventis (NYSE:SNY) said on Friday that its position on the Genzyme (NASDAQ:GENZ) takeover has not changed since last Sunday, when the French company made an offer to purchase Genzyme.
The two companies announced this week that they are in talks for a takeover, which would include a cash component of around $70 to $71 with a contingent value right, according to a Reuters report.
Continue Reading Below
On Friday, Sanofi confirmed that two patients taking its Multaq heart drug experienced liver failure, but did not say there was a link. The U.S. Food and Drug Administration issued a drug safety notice on the subject even without the cause proven.